These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 30763224)

  • 1. Precision Versus Traditional Medicine-Clinical Questions Trigger Progress in Basic Science.
    Schwartz PJ; Sala L
    Circ Res; 2019 Feb; 124(4):459-461. PubMed ID: 30763224
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of sodium channel block with mexiletine to reverse action potential prolongation in in vitro models of the long term QT syndrome.
    Sicouri S; Antzelevitch D; Heilmann C; Antzelevitch C
    J Cardiovasc Electrophysiol; 1997 Nov; 8(11):1280-90. PubMed ID: 9395171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of mexiletine in the management of long QT syndrome.
    Li G; Zhang L
    J Electrocardiol; 2018; 51(6):1061-1065. PubMed ID: 30497731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome.
    Shimizu W; Antzelevitch C
    Circulation; 1997 Sep; 96(6):2038-47. PubMed ID: 9323097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of atrial fibrillation with mexiletine pharmacotherapy in a young woman with type 1 long QT syndrome.
    El Yaman M; Perry J; Makielski JC; Ackerman MJ
    Heart Rhythm; 2008 Mar; 5(3):472-4. PubMed ID: 18313609
    [No Abstract]   [Full Text] [Related]  

  • 6. Broad antiarrhythmic effect of mexiletine in different arrhythmia models.
    Frommeyer G; Garthmann J; Ellermann C; Dechering DG; Kochhäuser S; Reinke F; Köbe J; Wasmer K; Eckardt L
    Europace; 2018 Aug; 20(8):1375-1381. PubMed ID: 29016765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of mexiletine on long QT syndrome model.
    Wang HW; Zheng YQ; Yang ZF; Li CZ; Liu YM
    Acta Pharmacol Sin; 2003 Apr; 24(4):316-20. PubMed ID: 12676070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reply: Did Mutation Type Affect the Efficacy of Mexiletine Observed in Patients With LQTS Type 3?
    Mazzanti A; Maragna R; Napolitano C; Priori SG
    J Am Coll Cardiol; 2017 Jan; 69(2):248-249. PubMed ID: 28081834
    [No Abstract]   [Full Text] [Related]  

  • 9. Molecular biology of the long QT syndrome: impact on management.
    Priori SG; Napolitano C; Paganini V; Cantù F; Schwartz PJ
    Pacing Clin Electrophysiol; 1997 Aug; 20(8 Pt 2):2052-7. PubMed ID: 9272507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Did Mutation Type Affect the Efficacy of Mexiletine Observed in Patients With LQTS Type 3?
    Hameed A
    J Am Coll Cardiol; 2017 Jan; 69(2):248. PubMed ID: 28081835
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of mexiletine on the canine model of sparfloxacin-induced long QT syndrome.
    Takahara A; Sugiyama A; Satoh Y; Hashimoto K
    Eur J Pharmacol; 2003 Aug; 476(1-2):115-22. PubMed ID: 12969756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of mexiletine on the canine cardiovascular system complicating cisapride overdose: potential utility of mexiletine for the treatment of drug-induced long QT syndrome.
    Satoh Y; Sugiyama A; Tamura K; Hashimoto K
    Jpn J Pharmacol; 2000 Aug; 83(4):327-34. PubMed ID: 11001179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic Effect of Dofetilide and Mexiletine on Prevention of Atrial Fibrillation.
    Liu G; Xue X; Gao C; Huang J; Qi D; Zhang Y; Dong JZ; Ma CS; Yan GX
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28522677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexiletine.
    Valdivia CR; Ackerman MJ; Tester DJ; Wada T; McCormack J; Ye B; Makielski JC
    Cardiovasc Res; 2002 Aug; 55(2):279-89. PubMed ID: 12123767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neonatal long QT syndrome type 3 predicted by positive lidocaine challenge.
    Howley LW; DI Maria M; Bailey A; Schaffer MS
    Pacing Clin Electrophysiol; 2010 Mar; 33(3):377-9. PubMed ID: 19793370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Congenital long QT syndrome with functionally impaired atrioventricular conduction: successful treatment by mexiletine and propranolol.
    Yao CT; Wang JN; Tsai YC; Lin CS; Wu JM
    J Formos Med Assoc; 2002 Apr; 101(4):291-3. PubMed ID: 12101867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients.
    Hu RM; Tester DJ; Li R; Sun T; Peterson BZ; Ackerman MJ; Makielski JC; Tan BH
    Channels (Austin); 2018; 12(1):176-186. PubMed ID: 29983085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mexiletine in a Newborn with Type 3 Long QT Syndrome: When Access is Difficult.
    Pereira ENS; Sacilotto L; Pessente GD; Guirao C; Carvalho MLP; Pereira ADC; Darrieux FCDC; Scanavacca MI
    Arq Bras Cardiol; 2022 May; 118(5):989-991. PubMed ID: 35613201
    [No Abstract]   [Full Text] [Related]  

  • 19. The long QT syndrome: new diagnostic and therapeutic approach in the era of molecular biology.
    Priori SG; Cantù F; Schwartz PJ
    Schweiz Med Wochenschr; 1996 Oct; 126(41):1727-31. PubMed ID: 8893413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological targeting of long QT mutant sodium channels.
    Wang DW; Yazawa K; Makita N; George AL; Bennett PB
    J Clin Invest; 1997 Apr; 99(7):1714-20. PubMed ID: 9120016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.